Sponsored by
ImmunityBio’s combination approach for recurrent glioblastoma (GBM) continues to show early promise. The Phase 2 QUILT-3.078 trial is testing NK-cell immunotherapy with Anktiva (an engineered IL-15 agonist), bevacizumab, and Optune. So far, 19 of 23 patients treated on the trial are still alive, and some have gone 12 months or more from recurrence without disease progression. Patients started the trial with very low lymphocyte counts from prior treatment, but the therapy helped restore immune function, and side effects have been manageable. While these results are still very early, we are watching this trial closely and hope to see further updates over the next few months!